YUMAB GmbH
Booth number 4517-04YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries.
About us
YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries.
YUMAB's integrated discovery and engineering platform offers highest success-rates to all types of antigens including “difficult” targets such as GPCRs, transporters or ion channels.
YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including superhumanization) and bioinformatic lead optimization.
Newest achievement is the fast track COVID-19 program of YUMAB's spin-off CORAT Therapeutics from target to patient in 11 months.
Address
YUMAB GmbH
Inhoffenstr. 7
38124 Braunschweig
Germany
Phone: +49 531 4811700
Internet: www.yumab.com
Products and Services
- Antibody Libraries
- Antibody Discovery
- Antibody Development
- Antibody Engineering
- Antibody Humanization
YUMAB® Antibody libraries
YUMAB® Antibody Library Features
- Natural antibody repertoires (no synthetic sequences)
- Universal and broad repertoire (all human frame works and CDR lengths)
- Large epitope coverage and high hit rate
- Flexible business conditions
YUMAB® Antibody discovery
YUMAB® Antibody discovery technologies.
- The power of in-vitro antibody selection.
- Challenging difficult targets by optimized discovery solutions.
- From target to lead.
News & Innovations
Discovery of a neutralizing antibody to treat Covid-19
Click here if you notice an image that violates copyright or privacy rights.